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The performance of six commercially available immunoassay systems for the detection of dengue virus-spe-
cific immunoglobulin M (IgM) and IgG antibodies in serum was evaluated. These included two IgM and IgG
enzyme immunoassays (EIA) from MRL Laboratories and PanBio, a rapid immunochromatographic test (RIT)
from PanBio, immunofluorescence assays (IFA) from Progen, a dot blot assay from Genelabs, and a dipstick
EIA from Integrated Diagnostics (INDX). For this study a panel of 132 serum samples, including 90 serum
samples from patients with suspected dengue virus infection and 42 serum samples from patients with other
viral infections, was used. In addition, serial serum samples from two monkeys experimentally immunized and
challenged with dengue virus type 2 were used. Results were considered conclusive when concordant results
were obtained with four of the six antibody-specific assays. Based on this definition, the calculated overall
agreement for the human serum samples for the respective IgM immunoassays was 97% (128 of 132), with 34%
(45 of 132) positive serum samples, 63% (83 of 132) negative samples, and 3% of samples (4 of 132) showing
discordant results. The calculated overall agreement for the IgG assays was 94% (124 of 132), with 49% (65 of
132) positive, 45% (59 of 132) negative, and 6% (8 of 132) discordant results, respectively. The sensitivities of
the dengue virus-specific assays evaluated varied between 71 and 100% for IgM and between 52 and 100% for
IgG, with specificities of 86 to 96% and 81 to 100%, respectively. The relative sensitivities of the respective IgM
assays measured with the monkey serum samples were comparable with those obtained with 12 serial serum
samples from humans. Overall performance, based on the sum of the agreement, sensitivity, specificity, and
Kappa statistics of the IgM and IgG immunoassays, showed that the antibody detection systems from INDX
and Genelabs and the MRL and PanBio EIA are useful and reliable assays for dengue virus serodiagnosis.
Dengue virus (DEN) infections are among the most com-
mon arthropod-borne infections in tropical and subtropical
areas. The four serotypes, DEN 1, DEN 2, DEN 3, and DEN
4, are transmitted by several mosquito species including Aedes
aegypti and Aedes albopictus. At least 50 million people are
infected with one of the four serotypes annually (3). The ma-
jority of DEN infections are asymptomatic or cause mild den-
gue fever (DF), characterized by flu-like symptoms including
fever, chills, headache, and myalgia. Rash, lymphadenopathy,
arthralgia, or myalgia usually follows these initial symptoms. In
some cases the infection may lead to the more severe dengue
hemorrhagic fever (DHF) with plasma leakage. Usually con-
junctival suffusion, facial flushing, and truncal erythema are
also present. The usually lethal dengue shock syndrome (DSS)
may follow DHF after circulatory collapse (6, 8).
Differential diagnosis may be important in order to distin-
guish DF from influenza, measles, rubella, other arthropod-
borne viral infections, malaria, and other hemorrhagic fevers
(15). Therefore, a good laboratory diagnosis is important. The
classic hemagglutination inhibition (HAI) assay and virus neu-
tralization assay are still widely used, despite their tedious
nature (1, 4, 9). Recently other immunosystems for the diag-
nosis of DEN infection have become commercially available.
Among these are enzyme immunoassays (EIA), immunochro-
matographic assays, and a dot blot assay (2, 10, 11, 12, 13, 16).
Differences in assay formats, usage of antigen, and detection
systems make it difficult to estimate the value of each individ-
ual assay without proper comparison. This prompted us to
evaluate six commercially available immunoassay systems for
the detection of DEN-specific immunoglobulin M (IgM) and
IgG antibodies. Ninety serum samples, both single and serially
collected from European and Asian patients with suspected
acute DEN infections, and 42 serum samples from Dutch pa-
tients with confirmed viral infections other than DEN infection
were used to evaluate 11 different assays from five companies.
In addition, serial serum samples from experimentally vacci-
nated monkeys subsequently challenged with DEN 2 were used
to study their antibody kinetics in the respective assays.
MATERIALS AND METHODS
Human serum samples. A panel of 132 human serum samples from patients
with suspected DEN infections and patients with other viral infections were
included in this study. Serial serum samples were collected from patients with
suspected acute DEN infections, living in areas of DEN endemicity. Thirteen
patients from Curaçao, with seven paired samples and six single serum samples
(n 5 20), and 6 patients with paired samples (n 5 12) and 12 patients with serial
samples (n 5 36) from Indonesia were included. Serum samples from patients
with suspected primary DEN infections (n 5 22), comprising 16 single serum
samples and 3 paired samples (n 5 6), were collected from Dutch travelers. As
controls, serum samples from patients with other viral infections confirmed by
the detection of specific IgM antibodies were used. These included sera with
specific IgM antibodies to Epstein-Barr virus (EBV) (n 5 5), cytomegalovirus
(CMV) (n 5 8), yellow fever virus (YFV) (n 5 4), varicella-zoster virus (VZV)
(n 5 8), herpes simplex virus (HSV) (n 5 6), and tick-borne encephalitis virus
(TBEV) (n 5 2). Eight samples from chronically infected patients with hepatitis
B virus (HBV) (n 5 8) were also included.
All samples had been collected between 1993 and 1998 and stored at 220°C
until use.
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Monkey serum samples. Serum samples from two cynomolgus monkeys (Ma-
caca fascicularis) experimentally immunized with live attenuated DEN 2 vaccine
and subsequently challenged with homologous wild DEN 2, as previously de-
scribed, were included in this study (14). Serum samples were collected at dif-
ferent times after immunization and challenge and were stored at 220°C until use.
IgG and IgM assays. The characteristics of the respective immunoassays are
depicted in Table 1. Included in this evaluation are two EIA, an immunofluo-
rescence assay (IFA), a rapid immunochromatographic test (RIT), a DipStick
EIA, and an immunoblot assay (blot). The MRL EIA (MRL Diagnostics, Cy-
press, Calif.) and the PanBio EIA (PanBio, Brisbane, Australia) are both based
on indirect systems for the detection of IgG serum antibodies using microwell
plates coated with the DEN 1 through DEN 4 antigens. The detection of IgM
serum antibodies for both these EIA is based on an IgM capture system followed
by an incubation with DEN 1 through DEN 4 antigens and virus-specific mono-
clonal antibodies conjugated with horseradish peroxidase. For the detection of
IgG serum antibodies, the assay times are 2 h with the MRL EIA and 1 h with
the PanBio EIA; for the detection of IgM serum antibodies, the assay time is 4 h
with the MRL EIA and 2 1/2 h for the PanBio EIA. The PanBio RIT is a rapid
(7-min) assay based on a capture principle for the detection of IgM and IgG
serum antibodies followed by an incubation with a mixture of DEN 1 through
DEN 4 antigens and a gold-labeled DEN-specific monoclonal antibody. The IFA
from Progen Biotechnik (Heidelberg, Germany) is based on an indirect system
for the detection of both IgM and IgG serum antibodies, using IFA slides coated
with DEN 2 antigen. To detect DEN-specific IgG antibodies, a goat anti-human
IgG-fluorescein isothiocyanate (FITC) conjugate (DAKO, Glostrup, Denmark)
was used. To detect DEN-specific IgM antibodies, the IgG-FITC conjugate was
replaced by a rabbit anti-human IgM-FITC conjugate (DAKO). Prior to the
detection of DEN-specific IgM antibodies by IFA, serum samples were pre-
treated with Gull-sorb (Gull Laboratories, Salt Lake City, Utah) to remove IgG
antibodies. The total assay time is 90 min for detection of IgG serum antibodies
and 2 h for IgM detection. The Integrated Diagnostics (INDX; Baltimore, Md.)
DipStick EIA is based on an indirect system for the detection of both IgM and
IgG serum antibodies. In this assay, a nitrocellulose membrane is coated with
DEN 2 antigen and binding antibodies are detected with an anti-human IgM or
IgG conjugate labeled with alkaline phosphatase. The assay times for detection
of IgM and IgG serum antibodies are 90 and 45 min, respectively. Finally, the
Genelabs Diagnostics (Singapore) blot is based on nitrocellulose membranes
coated with DEN 1 through DEN 4 antigens; binding IgG antibodies are de-
tected using a peroxidase-labeled protein A conjugate. IgG results were obtained
within 2 1/2 h. For the detection of IgM serum antibodies, the nitrocellulose
membranes are coated with anti-human IgM. After the binding of IgM antibod-
ies, the membranes are incubated with a mixture of DEN 1 through DEN 4
antigens, followed by incubation with a DEN-specific monoclonal antibody and
a rabbit anti-mouse Ig peroxidase-labeled conjugate, and are developed with
chloro-naphthol as the substrate. The minimum assay time is 8 h, although the
manufacturer recommends an overnight incubation with the antigen.
Monkey serum samples were analyzed for both IgM and IgG in the appropri-
ate assays according to the procedures described by the manufacturer, with
modifications as described below. In the Progen IFA an FITC-conjugated anti-
monkey IgM or anti-monkey IgG was used (DAKO) for detection of IgM and
IgG, respectively. In the Genelabs IgG blot, the protein A conjugate was re-
placed by an anti-monkey IgG-horseradish peroxidase conjugate (Sigma Chem-
ical Co., St. Louis, Mo.). It was not possible to detect IgG antibodies in the
monkey sera with the PanBio RIT.
Calculation, statistics, and ranking. The overall agreement, sensitivities, and
specificities of the respective assays were determined in relation to the consensus
values as the “gold standard” (17). Results were considered to be “true values”
(consensus values) when concordant results were obtained from at least four out
of the six assays. When three of the six assays were positive, the result was
defined as discordant. Kappa statistics were used to evaluate the level of agree-
ment between concordant results in excess of that expected by chance. If the
agreement reached a k value of 1, this indicated good agreement, while a k value
of 0 indicated no agreement (7). The ranking of each assay group (IgM and IgG)
was determined by the sum of the calculated k value, overall agreement, sensi-
tivity, and specificity. The overall ranking of each diagnostic system was deter-
mined by calculating the sum of the IgM and IgG rankings.
RESULTS
The overall agreement between all six immunoassays for the
detection of specific IgM and IgG antibodies against DEN in
the human sera is summarized in Table 2. Of the 132 samples
tested, 45 (34%) gave positive results, 83 (63%) gave negative
results, and 4 (3%) gave discordant results for DEN IgM se-
rum antibodies, while 65 (49%) gave positive results, 59 (45%)
gave negative results, and 8 (6%) gave discordant results for
DEN IgG serum antibodies.
The results of the individual assays with respect to the agree-
ment, sensitivity, specificity and k value, using the consensus
value as a “gold standard,” are summarized in Table 3. In
general, the level of agreement between the six IgM assays was
good (k 5 0.884 to k 5 0.966). The overall agreements of the
respective IgM assays varied from 88 to 98% for the PanBio
EIA (k 5 0.912) and PanBio RIT (k 5 0.966), respectively.
Sensitivities ranged from 100% for both the PanBio IgM RIT
and the Genelabs IgM blot to 71% for the Progen IgM IFA.
Specificities varied from 86% for the INDX EIA to 96% for
the PanBio EIA.
The overall agreement between the DEN-specific IgG assays
varied from 75 to 98% for the INDX EIA (k 5 0.913) and the
PanBio RIT (k 5 0.803), respectively. The level of agreement
between the respective DEN IgG immunoassays was relatively
TABLE 1. Characteristics of IgG and IgM assays for the detection of DEN antibodies
Company Type of assay Antigen Principle Serum dilution Total assay time (min)
MRL Diagnostics IgM EIA DEN 1, 2, 3, 4 Capture 1:101 240
IgG EIA DEN 1, 2, 3, 4 Indirect 1:101 120
PanBio IgM EIA DEN 1, 2, 3, 4 Capture 1:100 150
IgG EIA DEN 1, 2, 3, 4 Indirect 1:100 60
IgM-IgG RIT DEN 1, 2, 3, 4 Capture Undiluted 7
Progen Biotechnik IgM IFA DEN 2 Indirect 1:16 120
IgG IFA DEN 2 Indirect 1:16 90
INDX IgM DipStick EIA DEN 2 Indirect 1:200 90
IgG DipStick EIA DEN 2 Indirect 1:200 45
Genelabs Diagnostics IgM blot DEN 1, 2, 3, 4 Capture 1:100 480
IgG blot DEN 1, 2, 3, 4 Indirect 1:100 210
TABLE 2. Overall agreement of all the respective DEN-specific
IgM and IgG immunoassays according to the consensus model
Result
No. (%) of results for:
IgM IgG
Positivea 45 (34.1) 65 (49.2)
Negativeb 83 (62.9) 59 (44.7)
Discordantc 4 (3.0) 8 (6.1)
a Defined as positive results in at least four out of six assays.
b Defined as negative results in at least four out of six assays.
c Defined as positive results in three out of six assays and negative results in
three out of six assays.
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good (k 5 0.785 to k 5 0.917). High sensitivities of 100, 100,
and 97% were obtained with the MRL IgG EIA, PanBio IgG
EIA, and INDX IgG EIA, whereas the sensitivities of the
Genelabs IgG blot, Progen IgG IFA, and PanBio IgG RIT
were, respectively, 85, 77, and 52% compared to the consensus
value. Calculations of the specificities of these IgG assays re-
sulted in values between 86 and 100%.
Figure 1 presents the results of the performance of the six
different immunoassays for the detection of DEN IgM anti-
bodies measured in serial serum samples from 12 patients with
suspected acute DEN infections at different times after the
onset of clinical symptoms. During the acute phase, DEN-
specific IgM antibodies could be detected in seven patients’
samples with the Genelabs blot, whereas five patients tested
positive in the MRL, PanBio, and INDX EIA, six tested pos-
itive in the PanBio RIT, and four tested positive in the Progen
IFA. During the early-convalescent phase, IgM was detected
for 9 patients out of 12 in the Genelabs blot, for 8 patients in
the MRL EIA and the PanBio RIT, for 7 in the PanBio EIA
and the INDX, and for 4 in the Progen IFA. In the convales-
cent phase, DEN-specific IgM antibodies were detected for
nine patients with the MRL EIA and the Genelabs blot. Eight
patients’ samples were positive for the presence of DEN-spe-
cific IgM antibodies in the PanBio EIA, the PanBio RIT, and
the INDX. In the Progen IFA, seven patients tested positive.
Detection of DEN-specific IgM antibodies in the non-DEN
group varied from 0 to 6 positive samples out of 42 tested
serum samples. DEN-specific IgM serum antibodies were de-
tected in two samples (VZV) using the PanBio RIT, in three
samples (two HBV and one VZV) using the MRL IgM EIA, in
four samples (two HBV and two VZV) using the PanBio IgM
EIA, and in six samples (one CMV, one HBV, two HSV, one
VZV, and one TBEV) using the INDX IgM EIA. DEN-spe-
cific IgM serum antibodies were not detected using the Progen
IgM IFA or the Genelabs IgM blot. Measurement of serum
antibody reactivities of the 42 non-DEN serum samples by the
DEN-specific IgG assays showed four positive serum samples
with the MRL IgG EIA (one CMV, one TBEV, and two
VZV), three positive samples with the PanBio IgG EIA (one
TBEV and two VZV), five positive samples with the Progen
IgG IFA (two CMV, two TBEV, and one VZV), two positive
samples (both VZV) with the INDX IgG EIA, and three pos-
itive samples (one CMV, one EBV, and one VZV) with the
Genelabs IgG blot. All the non-DEN serum samples were
negative with the PanBio IgG RIT.
Figure 2 presents the kinetics of IgG and IgM antibodies to
DEN 2 in monkeys experimentally vaccinated and subse-
quently challenged with DEN 2, as measured by different as-
says. In monkeys E1 and E2, the IgM antibody kinetics mea-
sured by the quantitative IgM EIA from MRL and PanBio
showed identical patterns after immunization and challenge,
although the ratios measured by the IgM PanBio EIA were
slightly lower. In sera from monkey E1, the MRL EIA, the
PanBio EIA, and the PanBio RIT detected IgM antibodies on
TABLE 3. Agreement, specificity, sensitivity, and ranking of DEN antibody assays based on the consensus value
Assay
IgM detection IgG detection
Ranking
Agreement Sensitivity Specificity k Agreement Sensitivity Specificity k
MRL EIA 91 96 91 0.930 92 100 88 0.830 4
PanBio EIA 88 87 96 0.912 96 100 98 0.917 2
PanBio RIT 98 100 92 0.966 75 52 100 0.803 5
Progen IFA 83 71 89 0.884 82 77 86 0.785 6
INDX EIA 92 96 86 0.904 98 97 98 0.913 3
Genelabs blot 95 100 92 0.950 88 85 95 0.847 1
FIG. 1. Results of DEN-specific IgM detection of six different assays in sera from 12 patients with suspected acute DEN infections at different time points after the
onset of clinical symptoms. S1, serum sample in the acute phase; S2, serum sample in the early-convalescent phase; S3, serum sample in the convalescent phase.
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day 14, whereas the INDX EIA, blot and Progen IFA results
became positive on day 21. The PanBio RIT, PanBio IgM EIA,
and MRL IgM EIA remained positive for IgM antibodies
during the whole period. The EIA showed a gradual decrease
until 3 to 6 days after challenge with homologous DEN 2 virus.
In sera from monkey E2, lower IgM antibody responses were
detected as shown by the EIA. The Progen IFA remained
negative for IgM antibodies during the whole period.
DEN-specific IgG antibodies were detected only after chal-
lenge with homologous DEN 2 in all assays except the Progen
IFA, which was already positive on day 21 after immunization
and remained positive during the whole period.
DISCUSSION
Recently, a number of DEN-specific immunoassays have
become available for the detection of IgM and IgG antibodies
in serum, ranging from dipstick-based assays to more-sophis-
ticated enzyme-linked immunoassays. Some of these immuno-
assays have been evaluated in different studies (2, 10, 16). We
have evaluated 11 DEN immunoassays comprising 6 different
systems for the detection of IgM and IgG. Based on a consen-
sus model using serum samples from patients with suspected
DEN infections and non-DEN patients, the performance of
each assay was validated. In addition, the relative sensitivities
of the respective assays were studied with serial serum samples
from monkeys experimentally infected with DEN 2, followed
by homologous challenge with wild-type DEN 2 (14).
In general, all assays were easy to perform, but the simplest
and fastest assay to perform is by far the PanBio RIT. The
results of the PanBio RIT are available in less than 10 min, and
both IgM and IgG antibodies are detected simultaneously.
Except the Genelabs blot and the Progen IFA for detection of
IgM antibodies and the PanBio RIT for detection of IgG
antibodies, all the other DEN immunoassays detected nonspe-
FIG. 2. Detection by several assays of DEN-specific IgM and IgG antibodies in sera from two monkeys at different time points after experimental immunization
(day 0) and subsequent challenge (day 84) with homologous DEN 2. Shown are IgM (top) and IgG (bottom) results for monkey E1 (left) and monkey E2 (right). The
cutoff value (ratio of 1) is indicated by a dotted line. The respective assays are indicated on the right.
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cific DEN IgM and IgG serum antibodies. These reactions
were found mainly in patients with a CMV, EBV, or VZV
infection, in contrast to a previous study showing no DEN IgM
reactivity in serum samples from VZV, CMV, and EBV pa-
tients using the INDX DipStick EIA and a homemade DEN-
specific IgM capture EIA (16). Although the non-DEN serum
panel was carefully selected, using serum samples from pa-
tients in The Netherlands, where no flaviviruses are circulating,
the presence of flavivirus-specific IgG antibodies cannot be
completely ruled out. The TBEV and YFV vaccination sta-
tuses of the patients, as well as their histories of possible
flavivirus infections, were not available. DEN IgM and IgG
reactivities were detected by several assays in serum samples
from patients with TBEV infections. These flavivirus cross-
reactivities are in agreement with several other studies clearly
showing DEN antibody reactivity in patients with YFV and
Japanese encephalitis virus infections (2, 5, 16).
Serial serum samples from patients were used to evaluate
the respective DEN IgM assays in the acute, early-convales-
cent, and convalescent phase of disease. The results with these
serum samples clearly showed the best performance for the
Genelabs IgM blot assay and poor performance for the Progen
IgM IFA in the acute and early-convalescent phase. When
serial serum samples from humans with DEN infections are
used, the estimated time point after infection is variable.
Therefore, we used serial serum samples from monkeys exper-
imentally vaccinated and subsequently challenged with wild-
type DEN 2 to study the relative sensitivities of the IgM assays.
Despite the fact that the monkeys were vaccinated with DEN
2, which is the only virus present in the Vero cells coated on
the Progen slides, IgM antibodies could not be detected after
vaccination. The Progen IgG IFA, on the other hand, seems to
be more sensitive, compared to the other assays (Fig. 2).
Therefore, it is not yet clear why the Progen IgM IFA is not
performing as well as the other assays. In general, the results
obtained with the serial samples from humans, in particular
those for the Progen IgM, IFA, are in agreement with the rel-
ative sensitivities measured in the serial samples from the mon-
keys. The monkey samples in this study clearly show the value
of well-defined serial serum samples from experimentally in-
fected animals, since the results of these samples are not in-
fluenced by previous infections or vaccinations or by geograph-
ical background. These samples may also contribute to the
composition of quality control panels for flavivirus serology.
The consensus model resulted in an overall agreement of 45
IgM and 65 IgG DEN-positive serum samples, 83 IgM and 59
IgG DEN-negative serum samples, and 4 IgM and 8 IgG DEN-
discordant serum samples. On basis of this consensus model,
the calculated sensitivities of the DEN immunoassays evalu-
ated varied between 71 and 100% for the respective IgM assays
and between 52 and 100% for the respective IgG assays, with
specificities of 86 to 92% for the IgM assays and 86 to 100% for
the IgG assays.
The variations in sensitivity and specificity are comparable
with previously published data (2, 5) and might be caused by
the different principles of the assays, different antigens, conju-
gates (Table 1), or the selection of the respective serum panels.
In a multicenter evaluation using a commercial DEN IgM dot
assay, it was shown that the sensitivities varied between 80 and
98% depending on the serum samples of the respective collab-
orating centers (10).
Taken together, we conclude that the best complete DEN
IgM and IgG detection systems are the INDX DipStick EIA
and the PanBio EIA, followed by the MRL EIA and the
Genelabs blot, whereas the PanBio RIT and the Progen IFA
perform less well. If separate assays are selected to perform
DEN diagnosis in the laboratory, a combination of the PanBio
RIT for IgM detection and the PanBio IgG EIA would be the
most sensitive and specific combination. The PanBio RIT
seems to be in favor for bedside diagnostics and fieldwork
because of its high sensitivity and relatively high specificity for
IgM, and the simultaneously obtained IgG results are ignored.
In our view, for laboratories with a relative high workload of
DEN samples, a combination of the MRL IgM EIA and the
PanBio IgG EIA could be a good choice, since both assays can
easily be automated. The commercially available DEN immu-
noassay systems offer a good alternative to homemade DEN
assays, including HAI- and EIA-based systems. These com-
mercial assays make the serodiagnosis of DEN infection avail-
able to general and peripheral laboratories. However, for the
isolation, molecular diagnosis, and determination of DEN-spe-
cific neutralizing antibodies, reference laboratories will con-
tinue to play an important role, which will also be the case for
immunopathogenic, epidemiological, and vaccine studies.
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